Clinical Trials

Why We Offer Clinical Trials

The health care providers in the Department of Obstetrics, Gynecology, and Women’s Health are committed to continually improving the standard of care in all aspects of women’s health. Clinical trials are critical for advancing the field of gynecologic cancer prevention and treatment. They also provide patients with the opportunity for improved health outcomes and a higher quality of life. We are proud to offer cutting edge, innovative treatments that patients often cannot get elsewhere. We encourage all our patients to ask their doctor if a clinical trial is right for them. Ask your health care provider about clinical trials available to you for your specific condition.  

Institutional Review Board

The Institutional Review Board (IRB) reviews research projects involving human participants, working with investigators to ensure adequate protection and informed, uncoerced consent. The IRB approves all research involving human subjects to ensure that it is conducted in accordance with all federal, institutional, and ethical guidelines. Clinical trials are necessary to advance the field of gynecologic cancer prevention and treatment while also providing women the opportunity to obtain improved health outcomes and a higher quality of life.  

For Frequently Asked Questions about Clinical Trials, see our Clinical Trials FAQ.

Find all Clinical Trials by Disease


Gynecologic Cancer Clinical Trials

Ovarian Cancer Clinical Trials

Nanovary: Pembrolizumab for Ovarian Cancer of the Immunoreactive Subtype Recruitment Locations:

Tissue from the original ovarian cancer surgery is screened to verify if it fits the "immunoreactive" subtype. The immunotherapy pembrolizumab is then infused once every 3 weeks for up to 2 years.

• University of Minnesota - M Health Gynecologic Cancer Clinic
ALTOR: ALT-803 Maintenance After First Line Chemotherapy Recruitment Locations:

ALT-803 activates the body's immune system to increase the time that it takes for cancer to recur. ALT-803 is given after initial chemotherapy.

• University of Minnesota - M Health Gynecologic Cancer Clinic

 

 

ENDOMETRIAL CANCER CLINICAL TRIALS

Exemestane: Exemestane Prior to Hysterectomy for Endometrial Disease Recruitment Locations:
Exemestane is taken by mouth for 3 weeks prior to surgical removal of the uterus (hysterectomy). The goal of reducing the ability of the tumor to grow. • University of Minnesota - M Health Gynecologic Cancer Clinic
 

Cervical Cancer Clinical Trials

NRG GY-006: Triapine in Addition to Standard Chemoradiation Recruitment Locations:
Either Triapine or placebo is added to standard chemoradiation treatments. Triapine blocks a key enzyme needed for cancer growth, and may improve outcomes when added to front-line chemoradiation.  • Univeristy of Minnesota - M Health Gynecologic Cancer Clinic

Vaginal Cancer Clinical Trials

NRG GY-006: Triapine in Addition to Standard Chemoradiation Recruitment Locations:
Either Triapine or placebo is added to standard chemoradiation treatments. Triapine blocks a key enzyme needed for cancer growth, and may improve outcomes when added to front-line chemoradiation. • Univeristy of Minnesota - M Health Gynecologic Cancer Clinic
  • Developmental Therapeutics Clinic
  • Developmental Therapeutics Clinic

    Clinic Information
    The Development Therapeutics Clinic will be housed at the M Health Fairview Clinics and Surgery Center, 2nd Floor, on Wednesday mornings from 8 am to 12 pm. Referring physicians and patients can get more information by contacting the Masonic Cancer Center Nurse Information line at ccinfo@umn.edu or call the M Health Fairview Cancer Care line at 855-486-7226.

    CLICK HERE for more information and a list of the clinic oncologists.